Thus, anti-PD-1 immunotherapy gradually replaced traditional cetuximab-based regime or chemotherapy and is established as standard first-line treatment in R/M HNSCC 2. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.